11. (Journal Article): Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W
 
ABSTRACT: Integrated insulin secretion rates calculated from peripheral venous C-peptide measurements by two-compartment kinetic analysis were measured in six young normal subjects after inc...

12. (Journal Article): Gastric inhibitory polypeptide: the neglected incretin revisited.

Meier JJ, Nauck MA, Schmidt WE, Gallwitz B
 
ABSTRACT: After the ingestion of fat- and glucose-rich meals, gut hormones are secreted into the circulation in order to stimulate insulin secretion. This so-called "incretin effect&quo...

13. (Journal Article): Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

Nauck MA, Meier JJ
 
ABSTRACT: Glucagon-like peptide 1 (GLP-1) was discovered as an insulinotropic gut hormone, suggesting a physiological role as an incretin hormone, i.e., being responsible, in part, for the h...

14. (Journal Article): The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.

Nauck MA, El-Ouaghlidi A
 
ABSTRACT: n.a.

15. (Journal Article): Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsu-linemic, stepped hypoglycemic clamp experiments in healthy volunteers.

Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH
 
ABSTRACT: Glucagon-like peptide 1 (GLP-1) and analogues are being evaluated as a new therapeutic principle for the treatment of type 2 diabetes. GLP-1 suppresses glucagon secretion, which co...